Needling Techniques for Knee Osteoarthritis

Needling Techniques for Tonifying Kidneys and Dredging Meridians for Knee Osteoarthritis: A Randomized Clinical Trial

The purpose of this open-label, thirty-nine weeks-long clinical study is to investigate the efficacy of acupuncture for Knee Osteoarthritis (KOA) as adjunctive therapy to conventional treatment in comparison to conventional therapy alone and assessment of its eventual prolonged effectiveness after nine and twenty-four weeks without treatment. The long-term effects of acupuncture on KOA are not yet confirmed. A safety assessment will be done.

It will be interesting to find possible additional benefits of acupuncture while treating knee/s with an advance determined acupuncture protocol for KOA and Kidney Deficiency Syndrome (KDS) since Traditional Chinese Medicine (TCM) theory connects KOA with KDS. Acupuncture treatment point prescription will use local points for KOA and non-local points with their influence on KOA through Kidney deficiency as a root cause.

The deep layered chronic pathological condition like KOA requires a higher number of acupuncture treatments. This study will provide three cycles of acupuncture treatments to participants of the Acupuncture (A) group, which are three weeks long each, with treatment frequency three times weekly. It is expected that the study design with twenty-seven acupuncture treatments of KOA in fifteen weeks achieves improvement with the KOA and Kidney Deficiency Syndrome (KDS), additionally. Also, treatment effectiveness on KOA and KDS is expected to persist at the final assessment nine weeks after the last acupuncture treatment. That could confirm the holistic aspect of TCM.

Sixty-four patients with symptomatic KOA will be randomly allocated into the A group or C group (standard care) according to their permanent, unique, and coincidental Personal Identification Number which is randomly given to all citizens in Croatia. Before the experiment starts participant's demographic and disease parameters of both groups will be compared at baseline. Prescribed acupuncture protocol will be provided firstly to the Acupuncture group. Objective assessments of therapeutic efficacy will be done by a physiatrist at three time-points: baseline, after final acupuncture treatment (15th Week), and at the 24th Week. Subjective evaluation of symptoms intensity, by participants, will be assessed by Western Ontario and McMaster University Arthritis Index (WOMAC) total score and subscales, Visual Analogue Scale (VAS), and Kidney Deficiency Syndrome Questionnaire (KDSQ) every three weeks till the 24th week (nine assessments with baseline one). Analgesics taken by participants in the last three days before every assessment will be recorded.

Participants from the study were promised to receive equal acupuncture treatment after completion of the experiment and belonging assessments if they were randomised into the non-acupuncture group (Control). So, the participants of the C group cross over and after the 24th week of this study start with the identical acupuncture treatment protocol.

This study added later the 10th identical assessment to both groups of participants to estimate the within-subject C group effect of the acupuncture treatment protocol and to estimate the duration of treatment effect in the A group 24 weeks after the last acupuncture treatment.

Also, in the 24th week was added the Lequesne index, as a more objective and clearer measure of symptomatic and functional improvement of the knees. Participants were asked to fill out the questionnaire according to the actual condition and according to a memory of "how it was before the experiment start".

Hypothesis: A decrease in symptom intensity could be achieved after treatment in the experimental group compared to the control.

Study Overview

• Status: Completed
• Conditions: Knee Osteoarthritis; Kidney Yin Deficiency; Kidney Yang Deficiency
• Intervention / Treatment: Procedure: Acupuncture; Drug: Conventional Medical Treatment

Detailed Description

The prevalence of KOA in practice is high and patients are well motivated for additional treatment regarding their pain and functional impairment. Symptoms of KOA are mainly pain in the knees and stiffness. Other manifestations of KOA include sequelae such as muscle weakness, poor balance, and joint distortion. KOA occurs in middle and old age. Pain is worse with joint usage and relieved by rest. Limitation of motion mainly results from osteophytes and synovial hyperplasia. Bony swelling reflects remodelling of the bones, cartilages, and synovial thickening. Joint deformity is a sign of advanced joint damage and squaring, subluxation could happen. Instability may be a sign of weakness of the muscle and joint instability.

The prototype of a patient with KOA is an older patient with pain and disturbed function in one or in both knees, with possible less pronounced symptoms like weakness, insomnia, depression, tinnitus, forgetfulness, feeling cold, hot, low back pain, thirst at night, urogenital symptoms related to deeply layered disorders (Kidney deficiency symptoms). By treating both causes simultaneously it is to be expected a reduction of the reactive symptoms is the main effect, but also patient could experience changes in the presentation of its root symptoms. The treatment effect could present better function of the knee and could induce a patient's better quality of life through influence on Kidney deficiency.

The acupuncture treatment strategy for KOA logically follows the TCM syndrome differentiation and understanding of its pathogenesis. In KOA, the treatment principle distinguishes the root as deficient and the branch as an excess condition. Weak root (Kidney and Blood deficiency) condition contributes to the formation of branch syndrome (bone Bi syndrome). Aspiration with treatment would be to tonify the Kidney and Blood, nourish Qi, expel evils, remove dampness, promote blood circulation, and remove the obstruction from the channels and collaterals.

The study design It is expected to confirm the therapeutical efficacy of acupuncture in the A group where acupuncture treatment is adjunctive to conventional as opposed to the C group which receives only conventional treatment (analgesics).

Recruitment of participants was done from the target population: patients in two Family Medicine practices with confirmed and symptomatic KOA. The study population was formed with: inclusion criteria - patient 50 years old or above with KOA for at least 6 months, painful knee in last month, radiographic changes of OA (Kellgren-Lawrence grade 2 or more) and signed informed consent, and exclusion criteria - if an intra-articular injection into knee within 3 months preceding entry of participant into study, severe chronic or uncontrolled concomitant disease, bleeding diathesis, or anticoagulant use.

Mostly all 64 patients will be recruited from Family practices. All medical data of participants are available to the investigator. After previously fulfilling the SOAP (Subjective, Objective, Assessment, Plan) form and after getting informed written consent from all, the study population will be randomly allocated into two groups according to order by size of their permanent, unique eleven numbers long Personal Identification Number (OIB), which is given to all citizens in Croatia by birth. Its first ten numbers are accidentally chosen digits and a last digit is a control number. Every second participant in the accidental order by size of OIB will belong to the same group. Odd ones will belong to the A and even numbers to the C group. Demographic and disease parameters will be compared between the two groups at baseline. All patients in the A and C groups will receive analgesics, which dosages could be modified according to the participant's needs. Analgesics include nonsteroidal anti-inflammatory drugs (NSAIDs) and/or tramadol in both trial groups. Taken doses of analgesics in both groups will be recorded at Weeks 0, 3, 6, 9, 12, 15, 18, 21, and 24 and the dose represents an average daily dose of analgesics in the last three days according to the statement of participants. The recorded dosage will be shown as the comparable dose of the selected representative, which will be ibuprofen as the most prescribed one. Given data will be statistically processed and analyzed.

Patients in the A group will start with acupuncture treatment in September 2021 with the first of three planned treatment cycles. Each of the three treatment cycles will be three weeks long, one therapeutic cycle consists of 9 treatments each, and each two acupuncture cycles will be separated by three weeks period without treatment. Patients will receive acupuncture treatments three times per week.

Acupuncture treatment protocol: local treatment points Dubi (ST-35), Neixiyan (EX-LE-4) and Heding (EX-LE-2), Xuehai (SP-10), Yanglingquan (GB-34), Yinlingquan (SP-9), Zusanli (ST-36), Sanyinjiao (SP-6), and points selection based on kidney deficiency syndrome Taixi (KI-3), Guanyuan (CV 4), and Shenshu (BL-23).

A disposable sterile acupuncture needle 0.30 × 40 mm will be used. The depth and angle procedure predict straight needling and 1-1.5 inches deep, with a mild reinforcing-reducing method for local points, further straight and 0.5-1 inch deep, reinforcing method for points based on KDS. The time of needling will be 30 minutes, and the time point of reinforcing and reducing manipulation will be every 10 minutes, three times in total.

Sample size The sample size was calculated based on the study published by Berman et al.,1999. The authors used a shorter treatment period than the one envisioned for the present study (8 vs. 15 weeks). For sample size calculation, the following data from the mentioned study were used: WOMAC total score in A and C study groups was comparable at the baseline. After 8 weeks of treatment, WOMAC total scores were in group A 28,08 (SD = 17,96), in group C 50,11 (SD = 14,52).

The sample size was calculated using the PASS software package, with envisioning a two-sided test with unequal variances: type I error 0,05, power 0,95. Group sample sizes of 16 and 16 (i.e. complete study population of 32 subjects) achieve 95,78% power to reject the null hypothesis of equal means when the population means difference is μ1 - μ2 = 28,1 - 50,1 = -22,0 with standard deviations of 18,0 for A group and 14,5 for C group, and with a significance level (alpha) of 0,050 using a two-sided two-sample unequal-variance t-test.

In this study, the treatment period will be significantly longer compared to the study used for the calculation and it is expected a certain proportion of subjects to drop off the study and be lost to follow-up, the study population will be doubled to a total of 64 subjects.

Research methods The clinical question "Could the prolonged design of acupuncture treatments on patients with knee osteoarthritis (KOA) decrease pain and improve the function of the knee joints, and additionally achieve positive effects on the debilitating symptoms of a Kidney deficiency as a root cause of KOA, measured by recognized questionaries?" arise. The outcomes that matter the most are determined under clinical questions.

Evaluation of the therapeutic effect of acupuncture on KOA will include renowned WOMAC, VAS, and KDSQ scores, drug dosages are taken at Weeks 0, 3, 6, 9, 12, 15, 18, 21, and 24. WOMAC is a renowned questionnaire used by health professionals to evaluate the condition of patients with KOA. It measures 5 items for pain, 2 for stiffness, and 17 for functional limitation. VAS continuous scale of 100 mm in length is a widely used and recognized scale for pain intense assessment. The KDSQ questionnaire is a valid and reliable measure for the evaluation of the Kidney Yin and Yang deficiency syndromes in Hong Kong Chinese middle-aged women, constructed by Chen et al., 2012. KDSQ represents a valid questionnaire for the assessment of Kidney deficiency in this study population.

Participants from the study were promised to receive equal acupuncture treatment after completion of the experiment and belonging assessments if they were randomised into the non-acupuncture group (Control). So, the participants of the C group cross over and after the 24th week of this study start with the identical acupuncture treatment protocol.

This study added later the 10th identical assessment to both groups of participants to estimate the within-subject C group effect of the acupuncture treatment protocol and to estimate the duration of treatment effect in the A group 24 weeks after the last acupuncture treatment.

Also, in the 24th week was added the Lequesne index, as a more objective and clearer measure of symptomatic and functional improvement of the knees. Participants were asked to fill out the questionnaire according to the actual condition and according to a memory of "how it was before the experiment start".

Data will be stored electronically on a database with secured and restricted access. Data transfer will be encrypted and any information capable of identifying individuals removed.

Study analysis. This study tends to evaluate the effect of acupuncture treatment in WOMAC total score at the end of the acupuncture treatment protocol (15th Week) as a primary outcome measure. The persistence of the treatment effect will be assessed on the 24th Week (nine weeks after the last treatment). Secondary outcome measures will be WOMAC subscales, VAS, and KDSQ scores, drug dosage taken according to the statement of participants, physiatrist's measures, and Lequesne index. Baseline data will be obtained before the start of acupuncture treatments. Endpoint measures at specified time periods will be calculated from outcome measures in comparison to data at the baseline point. The effect size will be calculated in the comparison between data in the A group and data in the C group. Efficacy should be determined for primary and secondary outcomes, respectively. The primary efficacy analysis will be based on the intention to treat analysis set, defined as all randomized subjects included in the statistical analysis and analyzed according to the group were originally allocated, regardless of if they received the treatment. Statistical comparisons for total and subscale scores based on the WOMAC will be made using a repeated-measure model with terms of values for measuring at Weeks 3, 6, 9, 12, 15, 18, 21, and 24, and baseline as a covariate. The treatment difference and its 95% confidence interval will be estimated from this model. The same approach will be used for analyzing the VAS score and KDSQ questionnaire. All statistical tests will be two-sided.

The physiatrist's assessment, in three time-points (baseline, 15th Week, and 24th Week) should be used as a controlled measure. It'll include standard physiatrist KOA measurements (knee and thigh circumference, range of motion of knee).

A participant will be considered to have withdrawn from the trial when consent is revoked or if the participant cannot be contacted or located. Participants will not be withdrawn from the trial for protocol violations. Withdrawal due to an adverse event should be distinguished from withdrawal due to insufficient response.

All adverse events will be recorded in the Adverse Event Report Form at every treatment. If happen adverse event will be followed until the resolution of the event occurs. The serious adverse event must be reported to Medical Ethical Committee.

Expected endpoints Is to be expected pain relief and increased joint movement. Secondly, it could be expected to diminish symptoms of Kidney deficiency, reduction of analgesics dosages, confirmation of acupuncture safety as a secondary outcome which should be considered supportive. WOMAC could be reduced by 20 and KDSQ by 15. KOA pain and drug dose taken could be reduced by half.

Lowering the intensity of symptoms of Kidney deficiency represents an additional value that can influent the life quality of patients.

Research adjectives This is a prospective, interventional, randomized, open-label, controlled trial. It is supported by recent scholarly, peer-reviewed literature. The research method reflects the approach needed to answer the research questions. Research is addressing a gap in the literature that would contribute new findings. The research topic is based on a tangible and cited problem. The research will be conducted with data collection and analysis, any deviations will be documented and approved by the study performer. The study is originally designed. The acupuncture treatment plan for KOA is obtained with the assistance of Professor Xueping Zhou. The tendency of study is to be relevant and made under high standards applied in research in medical fields.

Conditions for completing the project The study will be conducted in a Family Medicine practice which is led by the study performer. All financial and operating burdens will be funded from practice resources.

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Croatia
  • Zagreb, Croatia, 10000
    • Family Medicine Practice Svijetlana Perculija Durdevic, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 48 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Clinical diagnosis of Knee Osteoarthritis
• Knee Osteoarthritis for at least 6 months
• painful knee in last month
• radiographic changes of the knee (Kellgren-Lawrence grade 2 or more)
• signed informed consent
• participant can move independently

Exclusion Criteria:

• if the participant got knee intra-articular injection 3 months before his entry into the study
• uncontrolled malignant disease
• unstable heart disease
• advanced organ failure disease (NYHA III or IV, or a more than the twofold increase of creatinin, or marked dyspnea)
• unstable psychiatrist's disease
• bleeding diathesis
• anticoagulant use

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Acupuncture Group; Participants in Acupuncture group will get acupuncture treatments to their symptomatic knee/knees according to the study protocol. Acupuncture will be provided to participants in three cycles, each three weeks duration, with frequency three times weekly. Period between the cycles is three weeks long. Participants will get acupuncture as adjunctive therapy to conventional medical treatment (analgesic therapy) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.	Procedure: Acupuncture; Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.; Drug: Conventional Medical Treatment; Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.; Other Names: Analgesics
Active Comparator: Control Group; Participants in Control group will get their standard conventional treatment (analgesics) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.	Drug: Conventional Medical Treatment; Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.; Other Names: Analgesics

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
WOMAC score at treatment completion time points	Total score as a sum of all three subscales for pain, stiffness, functional limitation. The minimum value is 0 and the maximum value is 96, where the lower score/value represents a better outcome, and the higher score/value represents the worse outcome This measure estimates the immediate treatment effects of acupuncture on pain, stiffness and knee function at the completed acupuncture treatments time point.	15th Week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
VAS value at last assessment time point	Pain intensity assessment, with a range of scale between 0-100, where the lower value represents a better outcome, and the higher value represents a worse outcome. This measure estimates the treatment effect of acupuncture on pain at the last assessment time point.	24th Week
VAS value at complete acupuncture treatments time point	Pain intensity assessment, with a range of scale between 0-100, where the lower value represents a better outcome, and the higher value represents a worse outcome. This measure estimates the treatment effect of acupuncture on pain at the completed acupuncture treatments time point.	15th Week
VAS at the end of study-24 week after last treatment (A group), after last treatment (C group)	Pain intensity assessment, with a range of scale between 0-100, where the lower value represents a better outcome, and the higher value represents a worse outcome. This measure estimates the treatment effect of acupuncture on pain at the completed acupuncture treatments time point.	39th Week
KDSQ score at last assessment time point	Assessment of Kidney deficiency intensity symptoms, the minimum value is 0 and the maximum value is 69, where the lower score/value represents better outcome, and higher score/value represents the worse outcome. This measure estimates the treatment effect of acupuncture on Kidney deficiency symptoms intensity at the last assessment time point.	24th Week
KDSQ score at completed acupuncture treatments time point	Assessment of Kidney deficiency intensity symptoms, the minimum value is 0 and the maximum value is 69, where the lower score/value represents better outcome, and higher score/value represents the worse outcome. This measure represents the treatment effect. This measure estimates the treatment effect of acupuncture on Kidney deficiency symptoms intensity at the completed acupuncture treatments time point.	15th Week
KDSQ at the end of study-24 week after last treatment (A group), after last treatment (C group)	Assessment of Kidney deficiency intensity symptoms, the minimum value is 0 and the maximum value is 69, where the lower score/value represents better outcome, and higher score/value represents the worse outcome. This measure represents the treatment effect. This measure estimates the treatment effect of acupuncture on Kidney deficiency symptoms intensity at the completed acupuncture treatments time point.	39th Week
Drug dose taken by a participant at last assessment time point	Analgesic treatment could include various NSAIDs or/and tramadol. Before the start of the study, the participant's analgesic therapy will be recorded. All participants could self-manage the dosage of taken analgesics according to their needs, and take analgesics if needed. Recorded analgesics, further recalculated in the comparable dose of selective representative which will be ibuprofen (expressed in grams). Further, analgesic's average daily dosage taken by participants in the last three days before assessment (according to the participant's statement) will be expressed as the comparable dosage of ibuprofen, at every assessment. That will be the measure "Drug dose taken by participants". Decrease in drug dose taken by participants will represent a better therapeutic outcome, and increase in drug dose taken by participants will represent a worse therapeutic effect. This measure estimates the treatment effect of acupuncture on pain at the last assessment time point.	24th Week
Drug dose taken by a participant at completed acupuncture treatments time point	Analgesic treatment could include various NSAIDs or/and tramadol. Before the start of the study, participant's analgesic therapy will be recorded. All participants could self-manage dosage of taken analgesics according to their needs, and take analgesics if needed. Recorded analgesics, further recalculated in the comparable dose of selective representative which will be ibuprofen (expressed in grams). Further, analgesic's average daily dosage taken by participants in the last three days before assessment (according to the participant's statement) will be expressed as the comparable dosage of ibuprofen, at every assessment. That will be measure "Drug dose taken by participants". Decrease in drug dose taken by participants will represent a better therapeutic outcome, and increase in drug dose taken by participants will represent a worse therapeutic effect. This measure estimates the treatment effect of acupuncture on pain at the completed acupuncture treatments time point.	15th Week
Drug dose taken by a participant at the end of study- 24 week after last treatment (A group), after last treatment (C group)	Analgesic treatment could include various NSAIDs or/and tramadol. Before the start of the study, participant's analgesic therapy will be recorded. All participants could self-manage dosage of taken analgesics according to their needs, and take analgesics if needed. Recorded analgesics, further recalculated in the comparable dose of selective representative which will be ibuprofen (expressed in grams). Further, analgesic's average daily dosage taken by participants in the last three days before assessment (according to the participant's statement) will be expressed as the comparable dosage of ibuprofen, at every assessment. That will be measure "Drug dose taken by participants". Decrease in drug dose taken by participants will represent a better therapeutic outcome, and increase in drug dose taken by participants will represent a worse therapeutic effect. This measure estimates the treatment effect of acupuncture on pain at the completed acupuncture treatments time point.	39th Week
Knee active extension at last assessment time point	This objective measurement is taken by an independent Physiatrist. It is measured with a goniometer and is expressed in degrees. Knee active extension has a normal value is 0 where the higher score/value represents the worse outcome. This measure estimates the treatment effect of acupuncture on knee stiffness at the last assessment time point.	24th Week
Knee active extension at completed acupuncture treatments time point	This objective measurement is taken by an independent Physiatrist. It is measured with a goniometer and is expressed in degrees. Knee active extension has a normal value is 0 where the higher score/value represents the worse outcome. This measure represents the treatment effect of acupuncture on knee stiffness at the completed acupuncture treatments time point.	15th Week
Thigh circumference 15 centimetres above patellar superior margin at last assessment time point	This is an objective measurement taken by an independent Physiatrist that will include the difference of circumference of the thigh 15 centimetres above the patellar superior margin measured with a tape measure. The unit of measure is a centimetre. This measure could estimate a measure of muscular strength or knee activity. Increased differences could indicate increased muscular strength/knee function and decreased differences indicate worse muscular strength/knee function. This measure estimates the treatment effect of acupuncture on knee activity at the last assessment time point.	24th Week
Thigh circumference 15 centimetres above patellar superior margin at completed acupuncture treatments time point	This is an objective measurement taken by an independent Physiatrist that will include the difference of circumference of the thigh 15 centimetres above the patellar superior margin measured with a tape measure. The unit of measure is a centimetre. This measure could represent a measure of muscular strength or knee activity. Increased differences could indicate increased muscular strength/knee function and decreased differences indicate worse muscular strength/knee function. This measure estimates the treatment effect of acupuncture on knee activity at the completed acupuncture treatments time point.	15th Week
WOMAC score at last treatment time point	Total score as a sum of all three subscales for pain, stiffness, and functional limitation, the minimum value is 0 and the maximum value is 96, where the lower score/value represents better outcome, and higher score/value represents a worse outcome This measure represents the treatment effect of acupuncture on pain, stiffness and knee function at the last assessment time point.	24th Week
WOMAC at the end of study- 24 week after last treatment (A group), after last treatment (C group)	Total score as a sum of all three subscales for pain, stiffness, and functional limitation, the minimum value is 0 and the maximum value is 96, where the lower score/value represents better outcome, and higher score/value represents a worse outcome This measure represents the treatment effect of acupuncture on pain, stiffness and knee function at the last assessment time point.	39th Week
Knee active flexion at last assessment time point	This objective measurement is taken by an independent Physiatrist. It is measured with a goniometer and is expressed in degrees. For knee active flexion maximum value is 135 degrees, where the lower score/value represents a worse outcome, and the higher score/value represents a better outcome. This measure represents the treatment effect of acupuncture on knee function at the last assessment time point.	24th Week
Knee active flexion at completed acupuncture treatments time point	This objective measurement is taken by an independent Physiatrist. It is measured with a goniometer and is expressed in degrees. For knee active flexion maximum value is 135 degrees, where the lower score/value represents a worse outcome, and the higher score/value represents a better outcome. This measure represents the treatment effect of acupuncture on knee function at the completed acupuncture treatments time point.	15th Week
Knee circumference over the middle of the patella in the knee extended position at last assessment time point	This is an objective measurement taken by an independent Physiatrist that will include the difference of circumference of the knee measured with a tape measure. The unit of measure is a centimetre. This measure could represent a measure of knee inflammation and its deformation (abnormal bone growth). Increased values indicate a higher level of knee inflammation/deformation and decreased differences indicate a lower level of knee inflammation/deformation. This measure estimates the direct treatment effect of acupuncture on knee osteoarthritis at the last assessment time point.	24th Week
Knee circumference over the middle of the patella in the knee extended position at completed acupuncture treatments time point	This is an objective measurement taken by an independent Physiatrist that will include the difference of circumference of the knee measured with a tape measure. The unit of measure is a centimetre. This measure could represent a measure of knee inflammation and its deformation (abnormal bone growth). Increased values indicate a higher level of knee inflammation/deformation function and decreased differences indicate a lower level of knee inflammation/deformation. This measure estimates the direct treatment effect of acupuncture on knee osteoarthritis at the completed acupuncture treatments time point.	15th Week
Lequesne index at Week 24th effect size between A and C group participants	This is an algofunctional index of knee and hip osteoarthritis in the form of a questionnaire divided into three sections. Its score range from 0 (no pain and disability) to 24 (the greatest pain and disability). This index is added in the 24th week because of its clarity in the presentation of knee pain and disturbed function.	24th Week

Collaborators and Investigators

• Sponsor: Svijetlana Perculija Durdevic
• Collaborators: Nanjing University of Chinese Medicine, Xueping Zhou, Li Ren; School of Medicine, University of Zagreb, Pero Hrabac; Health Center Zagreb East, Ljiljana Karadakic
• Investigators: Principal Investigator: Svijetlana Perculija Durdevic, M.D., Family Medicine Practice Svijetlana Perculija Durdevic, MD

Study record dates

Study Major Dates

• Study Start (Actual): September 6, 2021
• Primary Completion (Actual): December 18, 2021
• Study Completion (Actual): June 12, 2022

Study Registration Dates

• First Submitted: August 8, 2021
• First Submitted That Met QC Criteria: August 14, 2021
• First Posted (Actual): August 20, 2021

Study Record Updates

• Last Update Posted (Actual): October 18, 2022
• Last Update Submitted That Met QC Criteria: October 16, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Acupuncture; Randomized; Reducing; Needling; Techniques; Reinforcing
• Additional Relevant MeSH Terms: Pathologic Processes; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Yin Deficiency; Yang Deficiency; Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Analgesics
• Other Study ID Numbers: 39603233785

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: IPD that underlies the results reported in this article after deidentification (text, tables, figures, and appendices) for qualified researchers. Approval of the request is a prerequisite to the sharing of data.
• IPD Sharing Time Frame: 3 months following publication, ending 3 years following article publication

IPD Sharing Access Criteria

Access to trial IPD can be requested by a qualified researcher engaging in independent scientific research.

For more information or to submit a request please contact svijetlana.perculija.durdevic@outlook.com

• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No